ReviewJournal of human genetics2025
Molecular genetics of dystrophinopathy.
Review in Journal of human genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Economic Burden of Duchenne Muscular Dystrophy: A Systematic Review.PharmacoEconomics · 2026Pooled it
- Current and Emerging Therapeutic Strategies for the Treatment of Duchenne Muscular Dystrophy.Genes · 2026Review
- Review
- Stepwise genetic testing strategy identified pathogenic variants in 10 Chinese duchenne muscular dystrophy patients.Frontiers in genetics · 2026Article
- The rise of rat models for Duchenne muscular dystrophy and therapeutic evaluations.Skeletal muscle · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Dystrophinopathies, including Duchenne and Becker muscular dystrophies, are caused by pathogenic variants in the DMD gene, which spans 2.5 Mb and encodes multiple tissue-specific dystrophin isoforms. Advances in molecular diagnostic techniques have expanded our ability to detect a broad spectrum of DMD variants, including exonic deletions/duplications, small variants such as single-nucleotide variants and indels, and intronic rearrangements that disrupt splicing. Transcriptomic and long-read genomic analyses have revealed previously undetectable mechanisms of variation, including pseudoexon inclusion, intronic polyadenylation, and repeat expansions, underscoring the importance of integrating RNA-level data and in silico predictions into diagnostics. Genotype-phenotype correlations are influenced by the type and location of variants and by other factors, such as naturally occurring exon skipping and modifier genes. For instance, partial dystrophin expression caused by exon skipping in patients with certain nonsense variants can result in a milder Becker-like phenotype. These findings highlight the clinical significance of functional assays, such as minigene splicing reporters and immunostaining, in refining variant interpretation. This review summarizes the spectrum of DMD variants and outlines a stepwise diagnostic approach that integrates genetic, transcriptomic, and computational data. Special consideration is given to subgroups, such as female carriers and patients with mild phenotypes, in whom molecular diagnosis can be particularly challenging. Although therapeutic strategies are not the primary focus of this article, accurate molecular diagnosis forms the foundation for guiding individualized care. Together, these insights emphasize the value of integrated multi-omic variant assessment in improving diagnostic accuracy and patient management for dystrophinopathies.
Identifiers
40596735What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.